Zynerba Pharmaceuticals to Highlight Data for ZYN002 CBD Gel at the 70th Annual Meeting of the American Epilepsy …

DEVON, Pa., Nov. 28, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that two posters relating to ZYN002, its patent-protected synthetic CBD gel,  have been selected for presentation at the upcoming 70th Annual Meeting of the American Epilepsy Society, including safety, tolerability and effects on cognition and mood changes in healthy volunteers and adult epilepsy patients with focal seizures. The meeting will be held December 2 – 6, 2016, in Houston, Texas.
“We are encouraged to see that data further supporting the safety profile of ZYN002 were chosen for presentation at this year’s Annual Meeting for the American Epilepsy Society,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “These data demonstrate that ZYN002 CDB gel is safe, well-tolerated and show no psychoactive effects across a

... read more at: http://satprnews.com/2016/11/28/zynerba-pharmaceuticals-to-highlight-data-for-zyn002-cbd-gel-at-the-70th-annual-meeting-of-the-american-epilepsy-society/